The FDA decision on Kala Pharmaceuticals Inc.’s (KALA) Inveltys, a product candidate for the treatment of inflammation and pain in ocular surgery patients, is expected on August 24, 2018.If approved, Inveltys could be the first FDA-approved twice-daily ocular corticosteroid indicated for the treatment of post-operative ocular inflammation and pain.In the U.S., the current market leaders for topical steroids that are used to manage and prevent complications from post-operative inflammation, are Lotemax products and Durezol.In February of this year, the FDA approved Icon Bioscience Inc.’s Dexycu, a dropless therapeutic designed to treat inflammation associated with cataract surgery.H.C. Wainwright analyst Ram Selvaraju estimates peak sales of Inveltys to be $280 million in 2029.KALA closed Wednesday’s (Jul 25) trading at $12.99, up 1.48%.